CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Rising prevalence of infectious diseases
4.1.2. Growing focus on immunisation programs
4.1.3. Government support for vaccine development
4.1.4. Company initiatives to enhance vaccine research and development
4.2. Market Restraints & Challenges
4.2.1. Insufficient access to vaccines
4.2.2. The high cost of vaccine development
4.3. Market Opportunities
4.3.1. Emerging markets
4.3.2. Focus on therapeutic vaccines
4.3.3. Use of adjuvants in vaccines
CHAPTER 5. GLOBAL VACCINES MARKET – BY TYPE
5.1. Monovalent vaccines
5.2. Multivalent vaccines
CHAPTER 6. GLOBAL VACCINES MARKET – BY TECHNOLOGY
6.1. Conjugate vaccines
6.2. Inactivated and subunit vaccines
6.3. Live attenuated vaccines
6.4. Recombinant vaccines
6.5. Toxoid vaccines
CHAPTER 7. GLOBAL VACCINES MARKET – BY DISEASE INDICATION
7.1. Pneumococcal Disease
7.2. DTP
7.3. Influenza
7.4. HPV
7.5. Meningococcal Disease
7.6. Polio
7.7. Rotavirus
7.8. Hepatitis
7.9. MMR
7.10. Varicella
7.11. Dengue
7.12. Herpes Zoster
7.13. Other Disease Indications
CHAPTER 8. GLOBAL VACCINES MARKET – BY ROUTE OF ADMINISTRATION
8.1. Intramuscular and Subcutaneous administration
8.2. Oral administration
8.3. Parenteral
8.4. Topical
8.5. Others
CHAPTER 9. GLOBAL VACCINES MARKET – BY END USER
9.1. Pediatric vaccines
9.2. Adult vaccines
CHAPTER 10. GLOBAL VACCINES MARKET - BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.2.4. Costa Rica
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Chile
10.3.4. Columbia
10.3.5. Others
10.4. Europe
10.4.1. U.K.
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Russia
10.4.7. Netherlands
10.4.10. Switzerland
10.4.9. Poland
10.4.10. Others
10.5. APAC
10.5.1. China
10.5.2. Japan
10.5.3. India
10.5.4. South Korea
10.5.5. Australia & New Zealand
10.5.6. Malaysia
10.5.7. Singapore
10.5.10. Others
10.6. Middle East & Africa
10.6.1. UAE
10.6.2. Saudi Arabia
10.6.3. Iran
10.6.4. Iraq
10.6.5. Qatar
10.6.6. South Africa
10.6.7. Algeria
10.6.10. Morocco
10.6.9. Nigeria
10.6.10. Egypt
10.6.11. Others
CHAPTER 11. GLOBAL VACCINES MARKET - COMPANY PROFILES
11.1. Pfizer Inc.
11.2. GlaxoSmithKline PLC
11.3. Merck & Co., Inc.
11.4. Sanofi
11.5. CSL Limited
11.6. Emergent Bio solutions
11.7. Johnson & Johnson
11.8. MedImmune, LLC
11.9. Astellas Pharma, Inc.
11.10. Serum Institute of India
11.11. Bavarian Nordic
11.12. Mitsubishi Tanabe Pharma Corporation
11.13. Daiichi Sankyo Company
11.14. Panacea Biotech
11.15. Biological E Limited
CHAPTER 12. GLOBAL VACCINES MARKET - COMPETITIVE LANDSCAPE
12.1. Market Share Analysis
12.2. Strategies adopted by top companies
12.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 13. MARKET INSIGHTS
13.1. Industry Experts Insights
13.2. Analysts Opinions
13.3. Investment Opportunities
CHAPTER 14. APPENDIX
14.1. List of Tables
14.2. List of Figures
